Semaglutide vs tirzepatide for weight loss in 2026

For chronic weight management, semaglutide and tirzepatide should be compared as exact FDA-approved products, not generic “GLP-1 shots.” Semaglutide activates the GLP-1 receptor; tirzepatide activates GIP and GLP-1 receptors. In a 72-week head-to-head trial in adults with obesity without diabetes, maximum tolerated tirzepatide produced greater average weight and waist reduction than semaglutide—but that trial used semaglutide up to 2.4 mg, not the 7.2 mg Wegovy HD dose FDA approved in March 2026. ¹²³

The trial does not choose a drug for an individual. Indication, cardiovascular or sleep-apnea context, contraindications, tolerability, pregnancy plans, other medicines, route and dose preference, coverage, supply, and the ability to monitor long-term all affect the decision.

Start with product names and labeled populations

Semaglutide is sold in different approved products for different indications and presentations; tirzepatide is too. Wegovy and Zepbound are the obesity-treatment brands relevant to this comparison. Ozempic and Mounjaro are not interchangeable marketing names for them, even though they contain semaglutide and tirzepatide respectively.

Read the current label on the product actually prescribed. WEGOVY labeling contains indication-specific information, dose escalation, contraindications, warnings, pregnancy guidance, interactions, and administration instructions. ⁴ Zepbound has its own label; a clinic should provide it rather than substitute a dose chart made for another product.

What SURMOUNT-5 does—and does not—show

SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to maximum tolerated tirzepatide 10 or 15 mg or semaglutide 1.7 or 2.4 mg. At week 72, estimated mean weight change was −20.2% with tirzepatide and −13.7% with semaglutide; waist change also favored tirzepatide. Gastrointestinal events were the most common in both groups and occurred mainly during escalation. ³

That is high-quality direct evidence for the tested population and regimens. It does not establish:

• the result for a person with type 2 diabetes or another excluded condition;
• superiority at every dose or after switching;
• an individual’s likely percentage change;
• comparative outcomes after stopping;
• comparative access, adherence, or cost in ordinary care;
• equivalence between approved and compounded products; or
• comparison against the 7.2 mg semaglutide dose approved later.

The trial was open-label and funded by tirzepatide’s manufacturer; readers should use the prespecified methods and results, not turn the headline into a guarantee.

The 2026 semaglutide update changes the denominator

FDA approved Wegovy HD, a 7.2 mg weekly semaglutide injection dose, in March 2026 for weight reduction and long-term maintenance in certain adults. ² That approval does not invalidate SURMOUNT-5, but it means “tirzepatide beat semaglutide” must be followed by the doses actually tested.

Do not escalate from 2.4 mg to 7.2 mg based on a clinic menu or old comparison chart. The current product labeling defines who the higher dose is for, titration, presentation, warnings, and administration. Ask which version is being prescribed and whether the pharmacy and device match it.

More milligrams cannot be compared across molecules as potency or value. A tirzepatide milligram is not a semaglutide milligram, and dose size is not a score.

Safety screening is product-specific

Both drug classes require a real medical history and medication review. FDA approval materials and labeling identify contraindication related to personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 and discuss gastrointestinal adverse reactions and other warnings. ¹⁴ Labels also address pregnancy and procedures or conditions that can interact with delayed gastric emptying or treatment effects.

Ask the prescriber to cover pancreatitis and gallbladder history, kidney risk during dehydration, severe gastrointestinal symptoms, diabetes medicines and hypoglycemia context, retinopathy context where relevant, mental-health history, pregnancy plans, contraception and oral-medication timing, upcoming anesthesia or sedation, and other medicines that affect weight or gastric emptying.

This is not a universal contraindication list. It is a prompt to use the current exact label and clinical history rather than a telehealth checkbox designed around payment.

Get a written response path for persistent vomiting, inability to keep fluids down, severe abdominal pain, allergic symptoms, symptoms of low blood sugar when relevant, pregnancy, or a procedure requiring fasting or anesthesia. A monthly shipment without clinical access is not a complete program.

Compounded products are a separate comparison

FDA-approved Wegovy and Zepbound are not the same regulatory products as compounded semaglutide or tirzepatide. FDA says compounded drugs are not FDA approved and identifies concerns involving fraudulent labels, salt forms, shipping, dosing errors, and products sold as “research use only.” ⁵

If compounding is proposed, ask which patient’s medical need cannot be met by an approved product, the active ingredient and form, concentration, dose in milligrams and measured volume, named pharmacy, prescriber, additions, beyond-use date, storage, and instructions. Do not translate units on a syringe between vials.

The 2026 compounding guide covers the shortage and essentially-a-copy boundary. A lower price or custom label does not make a compound a generic approved drug.

Access can outweigh theoretical efficacy

A product that cannot be obtained consistently, tolerated, monitored, or afforded may not produce the trial result. Compare formulary coverage, diagnosis requirements, prior authorization, refill cadence, dose availability, manufacturer program terms, cash price, travel refrigeration, and the plan if coverage changes.

Do not switch abruptly or stack medicines to use leftover supply. Switching requires a new prescribing plan that accounts for current dose, adverse effects, time since last dose, comorbidities, and new product labeling.

Long-term maintenance belongs in the initial discussion. Ask what care continues after the active-loss phase, how nutrition and resistance training support health and lean tissue, how other medicines are adjusted, and what happens if treatment pauses.

Weight percentage is not the only outcome

SURMOUNT-5’s primary comparison was percent body-weight change, with waist and threshold outcomes among key secondary measures. ³ An individual’s plan may also prioritize glucose, blood pressure, sleep-apnea treatment, mobility, fertility planning, medication burden, strength, or quality of life. The relevant outcome should match the approved indication and the person’s care plan.

Rapid loss can include lean as well as fat mass, while scale changes also reflect water and gastrointestinal contents. Ask how the program supports adequate nutrition and resistance activity when appropriate and how weakness, dizziness, persistent poor intake, or functional decline is evaluated. A proprietary body-composition score should not trigger dose escalation.

Set an evidence-based reassessment rather than a cosmetic deadline. Trial averages at 72 weeks cannot promise a wedding-date result, and faster is not automatically safer or more sustainable.

A precise comparison workflow

1. 1. Confirm the indication and product Name Wegovy, Wegovy HD, Zepbound or another exact product; match the person's condition and goal to current FDA labeling.
2. 2. Use the right evidence population Compare diabetes status, age, BMI context, comorbidities, dose, duration and endpoint with SURMOUNT-5 or product trials before citing an average.
3. 3. Screen current labels Review contraindications, warnings, pregnancy plans, medicines, GI history, gallbladder and pancreatic context, dehydration and procedures.
4. 4. Model tolerability and monitoring Write escalation, hold or reduction rules, follow-up schedule, labs when indicated, side-effect access and urgent-contact instructions.
5. 5. Verify regulatory and supply status Separate approved brand from compounded product; record pharmacy, packaging, concentration, dose units, storage and supply contingency.
6. 6. Compare long-term access Calculate clinical and medication costs, coverage renewal, maintenance, refill reliability, switching plan and what happens after a pause.

The most accurate 2026 answer is conditional: tirzepatide led the tested head-to-head regimen, while product choice still depends on a different label, a newer semaglutide dose, individual risk, and sustainable access.